These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15282676)

  • 1. Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature review.
    Komrokji R; Ifthikharuddin JJ; Felgar RE; Abboud CN; Wedow LA; Connaughton A; Bennett JM
    Am J Hematol; 2004 Aug; 76(4):389-94. PubMed ID: 15282676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome.
    Solomon SR; Savani BN; Childs R; Montero A; Boss C; Read EJ; Leitman SF; Barrett AJ
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):619-26. PubMed ID: 16041312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome.
    Depil S; Deconinck E; Milpied N; Sutton L; Witz F; Jouet JP; Damaj G; Yakoub-Agha I;
    Bone Marrow Transplant; 2004 Mar; 33(5):531-4. PubMed ID: 14716345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
    Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous del(20q)-positive erythroid progenitor cells, re-emerging after DLI treatment of an MDS patient relapsing after allo-SCT, can provide a normal peripheral red blood cell count.
    Dykes JH; Lindmark A; Lenhoff S; Winqvist I; Johansson B; Olofsson T; Olsson ML
    Bone Marrow Transplant; 2004 Mar; 33(5):559-63. PubMed ID: 14716343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
    Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
    Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation from related and unrelated donors for aplastic anaemia in adults--a single-centre experience.
    Buchholz S; Dammann E; Koenecke Ch; Stadler M; Franzke A; Blasczyk R; Bremer M; Krauter J; Hertenstein B; Ganser A; Eder M
    Ann Hematol; 2008 Jul; 87(7):551-6. PubMed ID: 18386010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy.
    Bader P; Niemeyer C; Willasch A; Kreyenberg H; Strahm B; Kremens B; Gruhn B; Dilloo D; Vormoor J; Lang P; Niethammer D; Klingebiel T; Beck JF
    Br J Haematol; 2005 Mar; 128(5):649-58. PubMed ID: 15725087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation.
    Musso M; Porretto F; Crescimanno A; Polizzi V; Scalone R
    Bone Marrow Transplant; 2004 Apr; 33(7):769-71. PubMed ID: 14755320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Donor peripheral hematopoietic stem cells infusion for prophylaxis of relapse of high risk leukemia after allogeneic hematopoietic stem cell transplantation].
    Liu DH; Huang XJ; Chen H; Xu LP; Liu KY; Han W; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):6-9. PubMed ID: 16732930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7.
    Skinner R; Velangi M; Bown N
    Pediatr Blood Cancer; 2008 Mar; 50(3):670-2. PubMed ID: 17253642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
    Parody R; Martino R; Rovira M; Vazquez L; Vázquez MJ; de la Cámara R; Blazquez C; Fernández-Avilés F; Carreras E; Salavert M; Jarque I; Martín C; Martínez F; López J; Torres A; Sierra J; Sanz GF;
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):734-48. PubMed ID: 16785063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Allogeneic peripheral blood stem cell transplantation for a hepatitis B virus carrier with Epstein-Barr virus associated with hemophagocytic syndrome].
    Sakai R; Maruta A; Yamazaki E; Kamijo A; Taguchi J; Hyo R; Tanaka M; Fujimaki K; Nagao T; Yoshiba M; Ishigatsubo Y
    Rinsho Ketsueki; 2004 May; 45(5):397-401. PubMed ID: 15199750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.